Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

Akash Kumar, Ilsa Coleman, Colm Morrissey, Xiaotun Zhang, Lawrence D. True, Roman Gulati, Ruth Etzioni, Hamid Bolouri, Bruce Montgomery, Thomas White, Jared M. Lucas, Lisha G. Brown, Ruth F. Dumpit, Navonil DeSarkar, Celestia Higano, Evan Y. Yu, Roger Coleman, Nikolaus Schultz, Min Fang, Paul H. Lange & 3 others Jay Shendure, Robert L. Vessella, Peter S. Nelson

Research output: Contribution to journalArticle

200 Citations (Scopus)

Abstract

Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized. To determine whether the genomic alterations in a single metastasis provide a reasonable assessment of the major oncogenic drivers of other dispersed metastases in an individual, we analyzed multiple tumors from men with disseminated prostate cancer through whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling, and we compared the genomic diversity within and between individuals. In contrast to the substantial heterogeneity between men, there was limited diversity among metastases within an individual. The number of somatic mutations, the burden of genomic copy number alterations and aberrations in known oncogenic drivers were all highly concordant, as were metrics of androgen receptor (AR) activity and cell cycle activity. AR activity was inversely associated with cell proliferation, whereas the expression of Fanconi anemia (FA)-complex genes was correlated with elevated cell cycle progression, expression of the E2F transcription factor 1 (E2F1) and loss of retinoblastoma 1 (RB1). Men with somatic aberrations in FA-complex genes or in ATM serine/threonine kinase (ATM) exhibited significantly longer treatment-response durations to carboplatin than did men without defects in genes encoding DNA-repair proteins. Collectively, these data indicate that although exceptions exist, evaluating a single metastasis provides a reasonable assessment of the major oncogenic driver alterations that are present in disseminated tumors within an individual, and thus may be useful for selecting treatments on the basis of predicted molecular vulnerabilities.

Original languageEnglish (US)
Pages (from-to)369-378
Number of pages10
JournalNature medicine
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Tumors
Prostatic Neoplasms
Androgen Receptors
Automatic teller machines
Neoplasm Metastasis
Aberrations
Fanconi Anemia
E2F1 Transcription Factor
Genes
Cells
Neoplasms
Cell Cycle
Gene encoding
Protein-Serine-Threonine Kinases
Carboplatin
Cell proliferation
Exome
Activity Cycles
Comparative Genomic Hybridization
Retinoblastoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., ... Nelson, P. S. (2016). Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nature medicine, 22(4), 369-378. https://doi.org/10.1038/nm.4053

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. / Kumar, Akash; Coleman, Ilsa; Morrissey, Colm; Zhang, Xiaotun; True, Lawrence D.; Gulati, Roman; Etzioni, Ruth; Bolouri, Hamid; Montgomery, Bruce; White, Thomas; Lucas, Jared M.; Brown, Lisha G.; Dumpit, Ruth F.; DeSarkar, Navonil; Higano, Celestia; Yu, Evan Y.; Coleman, Roger; Schultz, Nikolaus; Fang, Min; Lange, Paul H.; Shendure, Jay; Vessella, Robert L.; Nelson, Peter S.

In: Nature medicine, Vol. 22, No. 4, 01.04.2016, p. 369-378.

Research output: Contribution to journalArticle

Kumar, A, Coleman, I, Morrissey, C, Zhang, X, True, LD, Gulati, R, Etzioni, R, Bolouri, H, Montgomery, B, White, T, Lucas, JM, Brown, LG, Dumpit, RF, DeSarkar, N, Higano, C, Yu, EY, Coleman, R, Schultz, N, Fang, M, Lange, PH, Shendure, J, Vessella, RL & Nelson, PS 2016, 'Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer', Nature medicine, vol. 22, no. 4, pp. 369-378. https://doi.org/10.1038/nm.4053
Kumar, Akash ; Coleman, Ilsa ; Morrissey, Colm ; Zhang, Xiaotun ; True, Lawrence D. ; Gulati, Roman ; Etzioni, Ruth ; Bolouri, Hamid ; Montgomery, Bruce ; White, Thomas ; Lucas, Jared M. ; Brown, Lisha G. ; Dumpit, Ruth F. ; DeSarkar, Navonil ; Higano, Celestia ; Yu, Evan Y. ; Coleman, Roger ; Schultz, Nikolaus ; Fang, Min ; Lange, Paul H. ; Shendure, Jay ; Vessella, Robert L. ; Nelson, Peter S. / Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. In: Nature medicine. 2016 ; Vol. 22, No. 4. pp. 369-378.
@article{d36731e076544e0cab3d308ccb1012f5,
title = "Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer",
abstract = "Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized. To determine whether the genomic alterations in a single metastasis provide a reasonable assessment of the major oncogenic drivers of other dispersed metastases in an individual, we analyzed multiple tumors from men with disseminated prostate cancer through whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling, and we compared the genomic diversity within and between individuals. In contrast to the substantial heterogeneity between men, there was limited diversity among metastases within an individual. The number of somatic mutations, the burden of genomic copy number alterations and aberrations in known oncogenic drivers were all highly concordant, as were metrics of androgen receptor (AR) activity and cell cycle activity. AR activity was inversely associated with cell proliferation, whereas the expression of Fanconi anemia (FA)-complex genes was correlated with elevated cell cycle progression, expression of the E2F transcription factor 1 (E2F1) and loss of retinoblastoma 1 (RB1). Men with somatic aberrations in FA-complex genes or in ATM serine/threonine kinase (ATM) exhibited significantly longer treatment-response durations to carboplatin than did men without defects in genes encoding DNA-repair proteins. Collectively, these data indicate that although exceptions exist, evaluating a single metastasis provides a reasonable assessment of the major oncogenic driver alterations that are present in disseminated tumors within an individual, and thus may be useful for selecting treatments on the basis of predicted molecular vulnerabilities.",
author = "Akash Kumar and Ilsa Coleman and Colm Morrissey and Xiaotun Zhang and True, {Lawrence D.} and Roman Gulati and Ruth Etzioni and Hamid Bolouri and Bruce Montgomery and Thomas White and Lucas, {Jared M.} and Brown, {Lisha G.} and Dumpit, {Ruth F.} and Navonil DeSarkar and Celestia Higano and Yu, {Evan Y.} and Roger Coleman and Nikolaus Schultz and Min Fang and Lange, {Paul H.} and Jay Shendure and Vessella, {Robert L.} and Nelson, {Peter S.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1038/nm.4053",
language = "English (US)",
volume = "22",
pages = "369--378",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

AU - Kumar, Akash

AU - Coleman, Ilsa

AU - Morrissey, Colm

AU - Zhang, Xiaotun

AU - True, Lawrence D.

AU - Gulati, Roman

AU - Etzioni, Ruth

AU - Bolouri, Hamid

AU - Montgomery, Bruce

AU - White, Thomas

AU - Lucas, Jared M.

AU - Brown, Lisha G.

AU - Dumpit, Ruth F.

AU - DeSarkar, Navonil

AU - Higano, Celestia

AU - Yu, Evan Y.

AU - Coleman, Roger

AU - Schultz, Nikolaus

AU - Fang, Min

AU - Lange, Paul H.

AU - Shendure, Jay

AU - Vessella, Robert L.

AU - Nelson, Peter S.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized. To determine whether the genomic alterations in a single metastasis provide a reasonable assessment of the major oncogenic drivers of other dispersed metastases in an individual, we analyzed multiple tumors from men with disseminated prostate cancer through whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling, and we compared the genomic diversity within and between individuals. In contrast to the substantial heterogeneity between men, there was limited diversity among metastases within an individual. The number of somatic mutations, the burden of genomic copy number alterations and aberrations in known oncogenic drivers were all highly concordant, as were metrics of androgen receptor (AR) activity and cell cycle activity. AR activity was inversely associated with cell proliferation, whereas the expression of Fanconi anemia (FA)-complex genes was correlated with elevated cell cycle progression, expression of the E2F transcription factor 1 (E2F1) and loss of retinoblastoma 1 (RB1). Men with somatic aberrations in FA-complex genes or in ATM serine/threonine kinase (ATM) exhibited significantly longer treatment-response durations to carboplatin than did men without defects in genes encoding DNA-repair proteins. Collectively, these data indicate that although exceptions exist, evaluating a single metastasis provides a reasonable assessment of the major oncogenic driver alterations that are present in disseminated tumors within an individual, and thus may be useful for selecting treatments on the basis of predicted molecular vulnerabilities.

AB - Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized. To determine whether the genomic alterations in a single metastasis provide a reasonable assessment of the major oncogenic drivers of other dispersed metastases in an individual, we analyzed multiple tumors from men with disseminated prostate cancer through whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling, and we compared the genomic diversity within and between individuals. In contrast to the substantial heterogeneity between men, there was limited diversity among metastases within an individual. The number of somatic mutations, the burden of genomic copy number alterations and aberrations in known oncogenic drivers were all highly concordant, as were metrics of androgen receptor (AR) activity and cell cycle activity. AR activity was inversely associated with cell proliferation, whereas the expression of Fanconi anemia (FA)-complex genes was correlated with elevated cell cycle progression, expression of the E2F transcription factor 1 (E2F1) and loss of retinoblastoma 1 (RB1). Men with somatic aberrations in FA-complex genes or in ATM serine/threonine kinase (ATM) exhibited significantly longer treatment-response durations to carboplatin than did men without defects in genes encoding DNA-repair proteins. Collectively, these data indicate that although exceptions exist, evaluating a single metastasis provides a reasonable assessment of the major oncogenic driver alterations that are present in disseminated tumors within an individual, and thus may be useful for selecting treatments on the basis of predicted molecular vulnerabilities.

UR - http://www.scopus.com/inward/record.url?scp=84959255550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959255550&partnerID=8YFLogxK

U2 - 10.1038/nm.4053

DO - 10.1038/nm.4053

M3 - Article

VL - 22

SP - 369

EP - 378

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -